DiaMedica Therapeutics Inc. (DMAC)
NASDAQ: DMAC · Real-Time Price · USD
3.770
-0.020 (-0.53%)
Apr 1, 2025, 3:51 PM EDT - Market open
DiaMedica Therapeutics Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for DiaMedica Therapeutics stock have an average target of 8.00, with a low estimate of 6.00 and a high estimate of 10. The average target predicts an increase of 112.20% from the current stock price of 3.77.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for DiaMedica Therapeutics stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
---|---|---|---|---|---|---|
Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
Buy | 1 | 1 | 1 | 1 | 1 | 1 |
Hold | 0 | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 3 | 3 | 3 | 3 | 3 | 3 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $7 → $10 | Strong Buy | Maintains | $7 → $10 | +165.25% | Mar 19, 2025 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +85.68% | Nov 15, 2024 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +85.68% | Oct 10, 2024 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $7 | Strong Buy | Initiates | $7 | +85.68% | Oct 7, 2024 |
Oppenheimer | Oppenheimer | Buy Reiterates $6 | Buy | Reiterates | $6 | +59.15% | Aug 16, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-0.78
from -0.60
EPS Next Year
-0.81
from -0.78
Revenue Forecast
Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | n/a | n/a | 11.7M | ||
Avg | n/a | n/a | 11.4M | ||
Low | n/a | n/a | 10.9M |
Revenue Growth
Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | - | - | - | ||
Avg | - | - | - | ||
Low | - | - | - |
EPS Forecast
EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | -0.70 | -0.72 | -0.97 | ||
Avg | -0.78 | -0.81 | -0.94 | ||
Low | -0.87 | -0.91 | -0.90 |
EPS Growth
EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | - | - | - | ||
Avg | - | - | - | ||
Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.